125 related articles for article (PubMed ID: 36084573)
1. The regulation of proliferation and apoptosis in hepatocellular carcinoma via insulin-like growth factor 1 receptor.
Xu G; Chu J; Shi Y; Huang L; Fu J
Growth Horm IGF Res; 2022 Oct; 66():101499. PubMed ID: 36084573
[TBL] [Abstract][Full Text] [Related]
2. IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways.
Cai W; Ma Y; Song L; Cao N; Gao J; Zhou S; Tang X
BMC Cancer; 2023 Jan; 23(1):87. PubMed ID: 36698167
[TBL] [Abstract][Full Text] [Related]
3. Ropivacaine suppresses tumor biological characteristics of human hepatocellular carcinoma via inhibiting IGF-1R/PI3K/AKT/mTOR signaling axis.
Zhang R; Lian Y; Xie K; Cai Y; Pan Y; Zhu Y
Bioengineered; 2021 Dec; 12(2):9162-9173. PubMed ID: 34696683
[TBL] [Abstract][Full Text] [Related]
4. Caveolin-1 Confers Resistance of Hepatoma Cells to Anoikis by Activating IGF-1 Pathway.
Tang W; Feng X; Zhang S; Ren Z; Liu Y; Yang B; lv B; Cai Y; Xia J; Ge N
Cell Physiol Biochem; 2015; 36(3):1223-36. PubMed ID: 26138883
[TBL] [Abstract][Full Text] [Related]
5. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells.
Ma J; Sawai H; Matsuo Y; Ochi N; Yasuda A; Takahashi H; Wakasugi T; Funahashi H; Sato M; Takeyama H
J Surg Res; 2010 May; 160(1):90-101. PubMed ID: 19560785
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
[TBL] [Abstract][Full Text] [Related]
7. miR-455-5p suppresses hepatocellular carcinoma cell growth and invasion via IGF-1R/AKT/GLUT1 pathway by targeting IGF-1R.
Hu Y; Yang Z; Bao D; Ni JS; Lou J
Pathol Res Pract; 2019 Dec; 215(12):152674. PubMed ID: 31732382
[TBL] [Abstract][Full Text] [Related]
8. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.
Chapuis N; Tamburini J; Cornillet-Lefebvre P; Gillot L; Bardet V; Willems L; Park S; Green AS; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Haematologica; 2010 Mar; 95(3):415-23. PubMed ID: 20007139
[TBL] [Abstract][Full Text] [Related]
9. Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop.
Bie C; Chen Y; Tang H; Li Q; Zhong L; Peng X; Shi Y; Lin J; Lai J; Wu S; Tang S
Dig Dis Sci; 2022 Feb; 67(2):569-584. PubMed ID: 33559791
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
11. Tanshinone IIA Attenuates Insulin Like Growth Factor 1 -Induced Cell Proliferation in PC12 Cells through the PI3K/Akt and MEK/ERK Pathways.
Wang H; Su X; Fang J; Xin X; Zhao X; Gaur U; Wen Q; Xu J; Little PJ; Zheng W
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30213025
[TBL] [Abstract][Full Text] [Related]
12. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression.
Bie CQ; Liu XY; Cao MR; Huang QY; Tang HJ; Wang M; Cao GL; Yi TZ; Wu SL; Xu WJ; Tang SH
Oncotarget; 2016 Nov; 7(48):79305-79318. PubMed ID: 27813495
[TBL] [Abstract][Full Text] [Related]
13. Bone morphogenetic protein 2 inhibits hepatocellular carcinoma growth and migration through downregulation of the PI3K/AKT pathway.
Zheng Y; Wang X; Wang H; Yan W; Zhang Q; Chang X
Tumour Biol; 2014 Jun; 35(6):5189-98. PubMed ID: 24573607
[TBL] [Abstract][Full Text] [Related]
14. Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway.
Xie L; Li M; Liu D; Wang X; Wang P; Dai H; Yang W; Liu W; Hu X; Zhao M
Molecules; 2019 Jan; 24(3):. PubMed ID: 30678274
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA deleted in lymphocytic leukaemia 1 promotes hepatocellular carcinoma progression by sponging miR-133a to regulate IGF-1R expression.
Zhang W; Liu S; Liu K; Liu Y
J Cell Mol Med; 2019 Aug; 23(8):5154-5164. PubMed ID: 31207081
[TBL] [Abstract][Full Text] [Related]
16. Curcumol induces cell cycle arrest and apoptosis by inhibiting IGF-1R/PI3K/Akt signaling pathway in human nasopharyngeal carcinoma CNE-2 cells.
Li X; Liu H; Wang J; Qin J; Bai Z; Chi B; Yan W; Chen X
Phytother Res; 2018 Nov; 32(11):2214-2225. PubMed ID: 30069933
[TBL] [Abstract][Full Text] [Related]
17. MiR-505 suppressed the growth of hepatocellular carcinoma cells via targeting IGF-1R.
Ren L; Yao Y; Wang Y; Wang S
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31160483
[TBL] [Abstract][Full Text] [Related]
18. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
Zhang Y; Moerkens M; Ramaiahgari S; de Bont H; Price L; Meerman J; van de Water B
Breast Cancer Res; 2011 May; 13(3):R52. PubMed ID: 21595894
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.
Bodzin AS; Wei Z; Hurtt R; Gu T; Doria C
J Cell Physiol; 2012 Jul; 227(7):2947-52. PubMed ID: 21959795
[TBL] [Abstract][Full Text] [Related]
20. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
